We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 127.51 | 200 | 11:10:54 |
From May 2021 to May 2024
By Josh Beckerman
The U.K. government has reached agreements to secure two Covid-19 antiviral treatments being developed, one by Merck & Co. with Ridgeback Biotherapeutics and one by Pfizer Inc.
The government secured 480,000 courses of molnupiravir, from Merck and Ridgeback, and 250,000 courses of Pfizer's PF-07321332/ritonavir.
The most vulnerable people would be eligible first, including the elderly and those with weakened immune systems, the government said.
A U.S. Food and Drug Administration advisory committee is expected to meet Nov. 30 to discuss the pill from Merck and Ridgeback. On Wednesday, the Bill & Melinda Gates Foundation announced today a commitment of up to $120 million to accelerate access to the drug for lower-income countries.
The U.K. government said the antiviral drugs "will be particularly vital in protecting those who may not get the same antibody response to the vaccines as the majority of the population."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 20, 2021 14:58 ET (18:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
